Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Family Medicine · PEORIA, AZ · NPI 1174560494
Verified facts
CMS Open Payments records show Linda E Leech, MD received $18.93 in general payments during 2025 across 1 reported records.
The Binding Site Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| The Binding Site Inc. | Unresolved — no canonical attribution shown | $18.93 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $18.93 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Freelite Normalized: freelite |
Device | The Binding Site Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 374 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 372 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 262 | 97 |
| Lisinopril | Lisinopril | 230 | 85 |
| Losartan Potassium | Losartan Potassium | 210 | 74 |
| Simvastatin | Simvastatin | 192 | 61 |
| Metformin Hcl | Metformin Hcl | 182 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 55 |
| Omeprazole | Omeprazole | 143 | 57 |
| Gabapentin | Gabapentin | 117 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 38 |
| Alendronate Sodium | Alendronate Sodium | 106 | 43 |
| Trazodone Hcl | Trazodone Hcl | 106 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 24 |
| Lovastatin | Lovastatin | 85 | 27 |
| Atenolol | Atenolol | 73 | 27 |
| Sertraline Hcl | Sertraline Hcl | 72 | 25 |
| Eliquis | Apixaban | 71 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 24 |
| Potassium Chloride | Potassium Chloride | 63 | 22 |
| Furosemide | Furosemide | 62 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 25 |
| Glipizide Er | Glipizide | 57 | 17 |
| Famotidine | Famotidine | 54 | 24 |
| Carvedilol | Carvedilol | 52 | 17 |
| Metformin Hcl Er | Metformin Hcl | 52 | 20 |
| Lorazepam | Lorazepam | 49 | 11 |
| Tramadol Hcl | Tramadol Hcl | 48 | 12 |
| Glipizide | Glipizide | 47 | 16 |
| Montelukast Sodium | Montelukast Sodium | 47 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 45 | 17 |
| Ozempic | Semaglutide | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 17 |
| Synthroid | Levothyroxine Sodium | 44 | 14 |
| Allopurinol | Allopurinol | 43 | 13 |
| Warfarin Sodium | Warfarin Sodium | 43 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 12 |
| Ezetimibe | Ezetimibe | 40 | 14 |
| Mirtazapine | Mirtazapine | 38 | 12 |
| Alprazolam | Alprazolam | 35 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 12 |
| Finasteride | Finasteride | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 11 |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Valsartan | Valsartan | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Olanzapine | Olanzapine | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18.93 · 1 records | The Binding Site Inc. | Freelite | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error